Published in Cancer Epidemiol Biomarkers Prev on October 27, 2009
Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet (2010) 2.51
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst (2011) 2.09
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. Biometrika (2012) 1.50
Simultaneously testing for marginal genetic association and gene-environment interaction. Am J Epidemiol (2012) 1.29
Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. Hum Mol Genet (2014) 0.90
Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Int J Cancer (2014) 0.90
Pooled versus individual genotyping in a breast cancer genome-wide association study. Genet Epidemiol (2010) 0.88
Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. Genet Epidemiol (2013) 0.86
Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. Immunogenetics (2011) 0.85
Empirical evaluation of gene and environment interactions: methods and potential. J Natl Cancer Inst (2011) 0.85
Genetic risk variants associated with in situ breast cancer. Breast Cancer Res (2015) 0.85
Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. Endocr Relat Cancer (2013) 0.83
Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. Am J Epidemiol (2011) 0.83
Association between rs2981582 polymorphism in the FGFR2 gene and the risk of breast cancer in Mexican women. Arch Med Res (2013) 0.82
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Res Treat (2013) 0.81
Association of cancer susceptibility variants with risk of multiple primary cancers: The population architecture using genomics and epidemiology study. Cancer Epidemiol Biomarkers Prev (2014) 0.80
Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med (2012) 0.79
FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer (2010) 0.79
Interaction between Common Breast Cancer Susceptibility Variants, Genetic Ancestry, and Nongenetic Risk Factors in Hispanic Women. Cancer Epidemiol Biomarkers Prev (2015) 0.78
FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. Carcinogenesis (2016) 0.78
Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer. BMC Womens Health (2012) 0.78
Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. Menopause (2013) 0.78
Identifying optimal biomarker combinations for treatment selection through randomized controlled trials. Clin Trials (2015) 0.75
Association of breast cancer risk loci with breast cancer survival. Int J Cancer (2015) 0.75
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet (2006) 13.16
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med (1994) 6.50
Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med (2004) 6.42
On estimating HLA/disease association with application to a study of aplastic anemia. Biometrics (1991) 4.81
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol (2001) 2.97
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis (2008) 2.03
Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol (2006) 1.96
Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol (2007) 1.95
Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene (2004) 1.77
The women's health initiative: lessons learned. Annu Rev Public Health (2008) 1.50
Aspects of the design and analysis of high-dimensional SNP studies for disease risk estimation. Biostatistics (2006) 1.38
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13
The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res (2008) 1.11
Case-only analysis of treatment-covariate interactions in clinical trials. Biometrics (2006) 1.05
Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration. Cancer Res (2005) 0.99
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science (2009) 21.24
Whole-genome patterns of common DNA variation in three human populations. Science (2005) 21.22
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet (2006) 13.16
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Common sequence polymorphisms shaping genetic diversity in Arabidopsis thaliana. Science (2007) 9.85
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet (2010) 9.07
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet (2006) 7.90
High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet (2005) 6.86
A sequence-based variation map of 8.27 million SNPs in inbred mouse strains. Nature (2007) 6.77
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst (2006) 6.41
Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet (2008) 6.06
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Fine-scale recombination patterns differ between chimpanzees and humans. Nat Genet (2005) 5.00
A genomewide admixture map for Latino populations. Am J Hum Genet (2007) 4.71
Genomewide SNP variation reveals relationships among landraces and modern varieties of rice. Proc Natl Acad Sci U S A (2009) 4.65
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Lung transplantation and survival in children with cystic fibrosis. N Engl J Med (2007) 4.57
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet (2006) 4.40
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Is it time to abandon the food frequency questionnaire? Cancer Epidemiol Biomarkers Prev (2005) 4.11
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol (2007) 3.88
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Detection of large numbers of novel sequences in the metatranscriptomes of complex marine microbial communities. PLoS One (2008) 3.83
A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet (2006) 3.77
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Genome characteristics of facultatively symbiotic Frankia sp. strains reflect host range and host plant biogeography. Genome Res (2006) 3.53
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
A genomewide single-nucleotide-polymorphism panel for Mexican American admixture mapping. Am J Hum Genet (2007) 3.39
Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med (2008) 3.34
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet (2009) 3.24
Matching strategies for genetic association studies in structured populations. Am J Hum Genet (2004) 3.13
Analysis of allelic differential expression in human white blood cells. Genome Res (2006) 3.07
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol (2013) 3.07
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst (2008) 3.04
The Next PAGE in understanding complex traits: design for the analysis of Population Architecture Using Genetics and Epidemiology (PAGE) Study. Am J Epidemiol (2011) 2.98
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97